• Deferasirox Fe3+ Chelate: Advanced Iron Chelation Workflows

  2026-07-31

  Deferasirox Fe3+ chelate empowers researchers with high-purity, DMSO-soluble performance for precise iron overload and lysosomal adaptation assays. This guide unpacks experimental protocols, troubleshooting strategies, and translational insights uniquely enabled by APExBIO’s flagship Exjade compound.

• MK-8745, Aurora A Inhibitor: Reliable Solutions for Cell-Bas

  2026-07-31

  This article provides a scenario-driven, evidence-based exploration of how MK-8745, Aurora A inhibitor, potent and selective (SKU A8807) addresses key laboratory challenges in cell viability and cancer research. Designed for biomedical researchers and lab technicians, it highlights protocol optimization, data reproducibility, and vendor selection for Aurora A inhibition workflows.

• BIIE 0246: Precision Neuropeptide Y Y2 Receptor Antagonist U

  2026-07-30

  BIIE 0246 is a benchmark neuropeptide Y Y2 receptor antagonist empowering advanced dissection of NPY signaling in neural, metabolic, and cardiovascular contexts. This guide translates cutting-edge findings into actionable protocols and troubleshooting strategies for researchers targeting feeding behavior, anxiety, and adipose-neural axis interactions.

• MLN4924: NEDD8-Activating Enzyme Inhibitor in Cancer Researc

  2026-07-30

  MLN4924 empowers cancer biology research by precisely inhibiting the neddylation pathway, offering robust experimental control over protein degradation and cell cycle regulation. This article guides scientists through optimized protocols, advanced applications, and troubleshooting strategies for leveraging MLN4924 in cutting-edge tumor models.

• EV-Transferred ACLY Drives Immunosuppressive TAM Differentia

  2026-07-29

  This study reveals a mechanism by which hepatocellular carcinoma (HCC) cells transfer ATP-citrate lyase (ACLY) to monocytes via extracellular vesicles, inducing their differentiation into tumor-associated macrophages (TAMs) with strong immunosuppressive properties. The findings highlight a novel, targetable axis in the tumor microenvironment that could improve the efficacy of immunotherapy for HCC.

• 3-Bromopyruvate and Cetuximab: Overcoming CRC Resistance via

  2026-07-29

  This study demonstrates that combined 3-bromopyruvate (3-BP) and cetuximab therapy overcomes resistance in colorectal cancer cells by triggering autophagy-dependent ferroptosis and apoptosis. The findings reveal new mechanistic insight into FOXO3a-driven pathways, offering a promising strategy for refractory colorectal cancer.

• MDV3100 (Enzalutamide): Scenario-Driven Solutions in Prostat

  2026-07-28

  This article delivers an evidence-based, scenario-driven guide for optimizing cell viability, proliferation, and cytotoxicity assays using MDV3100 (Enzalutamide), SKU A3003. Drawing on recent literature and practical lab workflows, it empowers researchers with actionable strategies to enhance reproducibility and mechanistic clarity in castration-resistant prostate cancer research.

• Trametinib (GSK1120212): Navigating Therapeutic Heterogeneit

  2026-07-28

  Delve into how Trametinib (GSK1120212) empowers researchers to dissect the complexities of therapeutic heterogeneity and drug resistance in cancer models. This cornerstone guide offers a unique, evidence-driven perspective on leveraging MEK-ERK pathway inhibition for advanced oncology research.

• Sumatriptan Succinate (SKU B4981): Reliable 5-HT1 Agonist fo

  2026-07-27

  This article explores how Sumatriptan (SKU B4981) from APExBIO addresses laboratory challenges in serotonergic signaling, cell viability, and migraine pathway assays. Grounded in peer-reviewed data and protocol-oriented guidance, it demonstrates why this compound is a dependable asset for rigorous, reproducible research.

• Optimizing RNA Extraction with DNase I (RNase-free): Protoco

  2026-07-27

  DNase I (RNase-free) from APExBIO delivers precise, ribonuclease-free DNA digestion for RNA extraction and RT-PCR workflows. Learn how to elevate your molecular biology experiments with evidence-based parameters, troubleshooting strategies, and insights from cutting-edge cancer stem cell research.

• O-GlcNAcylation Unlocked: Strategic Guidance with Thiamet G

  2026-07-26

  This article provides translational researchers with a mechanistic and strategic roadmap for leveraging Thiamet G, a selective O-GlcNAcase inhibitor, to modulate O-GlcNAcylation in disease models. With new evidence linking O-GlcNAc cycling to Wnt-induced bone formation and tauopathy, the discussion integrates experimental guidance, protocol considerations, and clinical relevance, while highlighting APExBIO’s Thiamet G as a cornerstone tool for next-generation research.

• Strategic Lipase Inhibition: CAY10499 in Immunometabolic Res

  2026-07-25

  This thought-leadership article explores how CAY10499, a potent inhibitor of human hormone sensitive lipase and monoglyceride lipase, enables translational researchers to dissect the mechanistic links between lipid metabolism, immune modulation, and tumor microenvironment remodeling. Building on the latest findings in extracellular vesicle-mediated metabolic reprogramming in hepatocellular carcinoma, the article provides actionable protocol guidance, evaluates the competitive landscape, and synthesizes a forward-looking perspective for immunometabolic research.

• Intestinal TM6SF2 Deficiency Drives MASH via Gut–Liver Axis

  2026-07-24

  This study uncovers that loss of TM6SF2 in intestinal epithelial cells promotes metabolic dysfunction-associated steatohepatitis (MASH) by disturbing gut barrier integrity and enhancing gut–liver axis signaling. Mechanistic insights reveal a central role for lipid signaling and microbial dysbiosis, highlighting new intervention points in MASH pathogenesis.

• Salmonella Haem Biosynthesis Suppresses Macrophage Phagocyto

  2026-07-24

  This study reveals a methyltransferase-driven mechanism by which Salmonella Typhimurium enhances haem biosynthesis to suppress macrophage phagocytosis, promoting bacterial virulence in mice. The findings clarify the post-translational regulation of heme pathway enzymes in immune evasion and highlight new directions for infection and translational research.

• Cy5 amine (non-sulfonated): Practical Guidance for Biomolecu

  2026-07-23

  Cy5 amine (non-sulfonated) addresses the need for a bright, photostable, amine-functionalized dye suitable for labeling biomolecules in non-aqueous fluorescence workflows. It is effective in sensitive fluorescence microscopy, flow cytometry, and molecular imaging applications where water-insolubility is required. This reagent should not be used in workflows demanding water solubility or for diagnostic/medical purposes.

459 records 10/31 page Previous Next First page 上5页 678910 下5页 Last page